济川药业：玛硒洛沙韦片是公司与南京征祥医药有限公司合作开发的化学药品1类新药，已获批上市

Core Viewpoint - The company has recently launched two new drugs, Maraslosavir Tablets and Pediatric Constipation Granules, which are categorized as innovative drugs and are expected to impact the company's performance positively [2]. Group 1: Drug Development and Approval - Maraslosavir Tablets is a Class 1 new chemical drug developed in collaboration with Nanjing Zhengxiang Pharmaceutical Co., Ltd., and has been approved for market launch [2]. - Pediatric Constipation Granules is a Class 1 innovative traditional Chinese medicine that has had its market approval application accepted, and the company is actively working on subsequent processes [2]. Group 2: Market Impact and Risks - The sales of these products may be influenced by changes in domestic pharmaceutical industry policies, tender procurement, and market environment, indicating potential uncertainties in their market performance [2].